Search Results

Deals

Verseon International Corporation, the company leading a technology-driven transformation of the pharmaceutical industry, announces that it has acquired Edammo, Inc.

October 18, 2022

·

2 min read

Deals

Verseon Acquires Edammo to Deepen Drug Discovery Approach

Verseon has acquired Edammo, an artificial intelligence-focused company, to deepen its own AI-based drug discovery platform. Financial terms were not disclosed.

October 14, 2022

·

4 min read

·

Mark Terry

Biotech Bay

Verseon Gains European Patent Protection for Potential Sight and Life-Saving Treatments

Verseon is pleased to announce that the European Patent Office has granted intellectual property protection covering novel chemical matter developed by Verseon that includes the company’s plasma kallikrein inhibitors (PKIs).

September 7, 2022

·

3 min read

An illustration of bond formation /courtesy of Ver

Drug Development

Verseon’s Atomic-Level Drug Design is Changing the Paradigm of Drug Discovery

What sets Verseon apart is its use of molecular physics modeling to enable the atomic-level engineering of new molecules. The company has 14 small molecule drugs in development.

May 2, 2022

·

5 min read

·

Gail Dutton

Biotech Bay

Verseon Corporation (“Verseon” or the “Company”): Result of AGM and Changes to the Board

Verseon Corporation announces that all resolutions put to shareholders were duly passed during the Annual General Meeting (“AGM”) held on November 5, 2018 at 14:00 PDT.

November 6, 2018

·

3 min read

Biotech Bay

Verseon Showcases Candidates for Next-Generation Diabetic Eye Disease Drugs

- Verseon presented their oral drug candidates for diabetic macular edema (DME) at this week’s 2019 BIO International Convention in Philadelphia.

June 4, 2019

·

3 min read

Biotech Bay

Verseon Presents Two Precision Oral Anticoagulants with Low Bleeding at International Stroke Conference

The new drug candidates, products of Verseon’s computationally driven drug discovery platform, could become the first anticoagulants suitable for long-term co-administration with antiplatelet drugs for patients with coronary artery disease.

February 11, 2019

·

3 min read

Drug Development

Verseon Reports First Dosing in Phase 1 Trial on New Precision Oral Anticoagulant

Verseon’s precision oral anticoagulants (PROACs) could become the first anticoagulants suitable for long-term co-administration with antiplatelet agents for the prevention of stroke and heart attack in coronary artery disease patients.

February 4, 2019

·

3 min read

Deals

Verseon Pioneers New Way of Funding Innovation Through Security Token Offering

Verseon is launching a security token offering aiming to set a new standard for the 21st century public offering to a globally connected investor base.

March 18, 2019

·

3 min read

Biotech Bay

Verseon Presents Oral Drug Candidate for Diabetic Eye Disease That Could Replace Eye Injections

Verseon presented promising preclinical efficacy data for the first development candidate for clinical trials in their diabetic eye disease program at this week’s ARVO 2019 annual meeting in Vancouver

April 30, 2019

·

3 min read